Abstract
Invasive Cervical carcinoma o Cervical Cancer (CCa) is the fourth leading cause of death among women. CCa is preceded by dysplastic alterations in the epithelial cells of the cervix that do not compromise the stroma. The most significant risk factor is one that is also required for the development of pre-invasive cervical lesions: persistent infection with a strain of human papilloma virus (HPV) that has a viral genotype. Timely detection programs consist of methods aimed at identifying women with asymptomatic pre-malignant lesions that can be healed with treatment. Current screening tests to detect CCa include cervical cytology, either conventional or liquid-based, and assays to detect high and low risk viruses or specific serotypes. Furthermore, because HPV is an etiological factor and because we know that primary prevention of HPV is a health-promoting strategy, prophylactic vaccines have been developed for this virus. Treatments for pre-malignant lesions depend on the degree of the lesion, the availability of medical resources, the experience of the surgeons in performing specific procedures and patient choice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, Fr Int Agency Res Cancer. 2013. http://globocan.iarc.fr. Accessed on day/month/yea.
Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99. doi:10.1016/S0140-6736(13)60022-7.
Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30. doi:10.1016/j.vaccine.2012.05.089.
Zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 1989;49:4677–81.
Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70–9. doi:10.1016/j.virol.2010.02.002.
Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int. 2013;2013:519619. doi:10.1155/2013/519619.
Szarewski A. Prophylactic HPV vaccines. Eur J Gynaecol Oncol. 2007;28:165–9. doi:10.2298/AOO0904068M.
Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–65. doi:10.1016/S0140-6736(04)17398-4.
Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–66.
CDC. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP). 2011. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22189893.
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.
Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99. doi:10.1016/S1470-2045(11)70286-8.
Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1–110.
Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106–14. doi:10.1001/jama.286.24.3106.
Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol. 2010;34:1077–87. doi:10.1097/PAS.0b013e3181e8b2c4.
Duarte-Franco E, Franco EL. Cancer of the Uterine Cervix. BMC Womens Health. 2004;4:S13. doi:10.1186/1472-6874-4-S1-S13.
Karjane N, Chelmow D. New cervical cancer screening guidelines, again. Obstet Gynecol Clin N Am. 2013;40:211–23. doi:10.1016/j.ogc.2013.03.001.
Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA J Am Med Assoc. 2002;287:2114–9. doi:10.1097/00006254-200208000-00015.
Tatti S, Bornstein J, Prendiville W. Colposcopy: a global perspective. introduction of the new IFCPC colposcopy terminology. Obstet Gynecol Clin N Am. 2013;40:235–50. doi:10.1016/j.ogc.2013.02.002.
Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340–5. doi:10.1016/j.ajog.2007.07.050.
Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995–3002. doi:10.1001/jama.285.23.2995.
Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1–S27. doi:10.1097/LGT.0b013e318287d329.
Castle PE, Glass AG, Rush BB, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012;30:3044–50. doi:10.1200/JCO.2011.38.8389.
Padilla-Paz LA, Carlson J, Twiggs LB, et al. Evidence supporting the current management guidelines for high-grade squamous intraepithelial lesion cytology. J Low Genit Tract Dis. 2004;8:139–46. doi:10.1097/00128360-200404000-00010.
Martin-Hirsch PP, Keep SL, Bryant A. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2010:CD001421. doi:10.1002/14651858.CD001421.pub2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
González-Enciso, A., Barquet-Muñoz, S.A., Cantú-de-León, D.F., Corea-Urbina, C.Y. (2017). Pre-invasive Lesions of the Cervix. In: de la Garza-Salazar, J., Morales-Vásquez, F., Meneses-Garcia, A. (eds) Cervical Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-45231-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-45231-9_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-45230-2
Online ISBN: 978-3-319-45231-9
eBook Packages: MedicineMedicine (R0)